• Caiyun Zheng, Hengfen Dai, Jungao Huang, Meimei Lin, Qiaowen Zheng, Pujing Tang, Jingwen Xiao, and Yan Zhang.
• Affiliated Fuqing City Hospital of Fujian Medical University Fuzhou 350300, China.
• Am J Transl Res. 2021 Jan 1; 13 (11): 12114-12128.

ObjectiveA meta-analysis of the studies involving Sacubitril/Valsartan in chronic heart failure was performed to compare the efficacy and safety of Sacubitril/Valsartan with traditional drug therapy in chronic heart failure.MethodsWe searched databases from PubMed, EMBASE, the Cochrane Library, Web of Science, and clinicaltrials.gov for studies published between 2010 and 2020 that reported efficacy and safety following Sacubitril/Valsartan administration.ResultsTen studies enrolling 1689 patients were included. Sacubitril/Valsartan outperformed traditional medicine (especially the Non-ARNI group) in terms of blood pressure, biomarkers and cardiac reverse remodeling indices, with striking changes in left ventricular ejection fraction, systolic blood pressure. Sacubitril/Valsartan showed significant benefit in renal function in patients with chronic heart failure.ConclusionsCompared with traditional drugs, Sacubitril/Valsartan significantly improved echocardiography, vital signs and biomarkers of patients with chronic heart failure, and reduced the incidence of hyperkalemia, renal dysfunction and other adverse reactions. Further large sample trials are needed in the future to determine the long-term effects of Sacubitril/Valsartan on efficacy and safety in patients with chronic heart failure.AJTR Copyright © 2021.

3 keywords...

hide…